PRPO - トランスジェノミック (Precipio Inc.) トランスジェノミック

 PRPOのチャート


 PRPOの企業情報

symbol PRPO
会社名 Precipio Inc (トランスジェノミック)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Precipio Inc. formerly Transgenomic Inc. is a biotechnology company. The Company is engaged in advancing personalized medicine for the detection and treatment of cancer and inherited diseases through its molecular technologies and clinical and research services. The Company operates through its Laboratory Services segment. The Company is engaged in the provision of its Multiplexed ICE COLD-PCR (MX-ICP) product to the clinical market enabling the use of blood and other bodily fluids for diagnosis monitoring and treatment of cancer. MX-ICP amplifies the ability to detect genetic mutations by approximately 100 to 400 fold. MX-ICP is validated internally on sequencing platforms including Sanger Next Gen Sequencing and Digital polymerase chain reaction (PCR). Its laboratory in Omaha Nebraska is focused on providing genetic analytical services related to oncology and pharmacogenomics research services supporting Phase II and Phase III clinical trials conducted.   トランスジェノミックは米国のバイオ企業。コネチカットとネブラスカ州の臨床検査室で心臓、神経、ミトコンドリア異常、がん疾患の遺伝子検査を行う。また、分子遺伝学研究と分子診断用の遺伝子解析システム「ウェ―ブ」を製造、販売するほか、他社の生体計測装置を販売。また、機器の据え付け、保守、技術サポ―トを提供。   Precipio Inc is a diagnostics company, which has built a platform designed to eradicate the problem of misdiagnosis by harnessing the expertise and technology developed within academic institutions and delivering diagnostic information to physicians.
本社所在地 4 Science Park New Haven CT 06511 USA
代表者氏名 Samuel D. Riccitelli サミュエルD.リッチェッテリ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 203-787-7888
設立年月日 35490
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 33人
url www.precipiodx.com
nasdaq_url https://www.nasdaq.com/symbol/prpo
adr_tso
EBITDA EBITDA(百万ドル) -7.68800
終値(lastsale) 0.3775
時価総額(marketcap) 8741341.68
時価総額 時価総額(百万ドル) 7.40988
売上高 売上高(百万ドル) 2.74400
企業価値(EV) 企業価値(EV)(百万ドル) 11.07688
当期純利益 当期純利益(百万ドル) -31.59900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Precipio Inc revenues increased from $508K to $1.5M. Net loss applicable to common stockholders decreased 6% to $9.1M. Revenues reflect Service revenue net increase from $619K to $1.7M. Lower net loss reflects Warrant revaluation increase from $3K (expense) to $584K (income) Interest expense net decrease of 85% to $56K (expense).

 PRPOのテクニカル分析


 PRPOのニュース

   Midday Gainers / Losers  2019-05-03
Gainers : Regional Health Properties (NYSEMKT: RHE ) +54% . Zix (NASDAQ: ZIXI ) +34% . Wesco Aircraft (NYSE: WAIR ) +28% . AAC Holdings (NYSE: AAC ) +25% . Maxar Technologies (NYSE: MAXR ) +23% . Idera Pharmaceuticals (NASDAQ: IDRA ) +22% . Mercer International (NASDAQ: M…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 トランスジェノミック PRPO Precipio Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)